Purchase Order Form Newborn Screening

COMMERCIAL PROCUREMENT & SERVICE ORDER: NEWBORN SCREENING (NBS) ASSAY & LOGISTICAL SERVICES

DOCUMENT CONTROL & METADATA

• Effective Date: [Effective Date]
• Document Version: 4.2-CORP-NBS
• Jurisdiction / Scope: Commercial Healthcare Operations, Clinical Diagnostics, and Compliance (United States / Global Compliance Framework)
• Governing Master Agreement: Master Services Agreement (MSA) dated [MSA Date] (if applicable)

---

1. LEGAL NOTICE & COMPLIANCE DISCLAIMER

CRITICAL REGULATORY NOTICE: This Purchase Order (PO) involves the procurement of specialized clinical diagnostics, biospecimen collection materials, and laboratory processing services for Newborn Screening (NBS). Both Purchaser and Vendor acknowledge and agree that all transactions executed hereunder are strictly subject to applicable federal, state, and international healthcare compliance frameworks, including but not limited to the Health Insurance Portability and Accountability Act (HIPAA), the Health Information Technology for Economic and Clinical Health (HITECH) Act, Clinical Laboratory Improvement Amendments (CLIA), and state-specific statutory mandates governing public health reporting and newborn screening retention.

Nothing in this document shall supersede any executed Business Associate Agreement (BAA) or Master Services Agreement between [Company Name] and the designated laboratory processing entity. Unauthorized reproduction, clinical misuse, or diversion of testing kits constitutes an immediate material breach and triggers statutory reporting obligations.

---

2. PARTIES & DEFINITIONS

For the purposes of this Purchase Order, the following entities and terms are defined and integrated herein:

• Purchaser / Healthcare Entity: [Purchaser Legal Name], having its principal place of business at [Purchaser Street Address, City, State, Zip], hereinafter referred to as "Purchaser".
• Vendor / Diagnostic Provider: [Vendor Legal Name], having its principal place of business at [Vendor Street Address, City, State, Zip], hereinafter referred to as "Vendor".
• Designated Clinical Laboratory: [Laboratory Name, CLIA Number: ____________________], authorized to perform high-complexity clinical assay testing.
• Effective Date: [Date of Issuance]
• Total Purchase Order Amount: USD [$0,000.00], inclusive of applicable taxes, regulatory surcharges, and freight.
• Payment Terms: Net [30] Days from receipt of compliant invoice and verified chain-of-custody delivery.

---

3. OPERATIVE CLAUSES & TERMS

3.1 Scope of Procurement & Deliverables

Vendor shall supply Purchaser with the exact quantities of Newborn Screening collection kits, reagents, transport media, and associated diagnostic processing services itemized in Schedule A (Order Schedule). All materials delivered must strictly comply with FDA clearance/approval standards, CLIA requirements, and state-mandated panel specifications.

3.2 Ordering, Delivery, and Risk of Loss

1. Fulfillment: Vendor shall ship all physical goods (e.g., blood collection filter paper cards, lancets, transport envelopes) to Purchaser’s designated facility located at [Delivery Facility Name and Address] no later than [Delivery Date].
2. Risk of Loss: Risk of loss and title for all physical collection materials shall pass to Purchaser upon verifiable delivery to the designated facility. Risk of loss for biospecimens returns to the custody of the courier/Vendor upon formal scan-in at the point of pickup.
3. Chain of Custody: Every shipment of collected newborn screening specimens must be accompanied by an electronic or physical chain-of-custody (CoC) manifest ensuring traceability from collection site to the clinical laboratory.

3.3 Quality Assurance, Reagents, and Expiration Standards

1. Shelf Life: All diagnostic collection kits delivered under this PO must possess a minimum remaining shelf life of not less than [12] months upon receipt at Purchaser’s facility.
2. Lot Tracking: Vendor shall maintain a robust lot-tracking system capable of identifying and instantly recalling compromised, expired, or out-of-specification assay lots pursuant to FDA and ISO 15189 standards.
3. Rejection of Substandard Goods: Purchaser reserves the right to inspect all deliverables upon receipt and reject any goods that exhibit packaging compromise, temperature excursions (if applicable), or expired components.

3.4 Pricing, Invoicing, and Payment

1. Fixed Pricing: Prices set forth in Schedule A are fixed for the duration of this PO and shall not be subject to escalation, fuel surcharges, or unapproved administrative fees.
2. Invoicing Requirements: Invoices must reference this Purchase Order Number ([PO-202X-XXXX]), CLIA identifiers, specific item SKUs, and must be transmitted electronically to [Billing Email Address].
3. Disputed Invoices: Purchaser may withhold payment for disputed line items pending resolution; undisputed amounts shall be paid within the agreed Net [30] Day window.

3.5 Regulatory Compliance & Patient Privacy (HIPAA / BAA)

1. PHI Protection: Vendor warrants that it complies with all provisions of HIPAA regarding Protected Health Information (PHI) and Personally Identifiable Information (PII) generated during the newborn screening lifecycle.
2. Business Associate Status: To the extent Vendor or its designated laboratory processes patient-identifiable specimens, the parties operate under the binding terms of the executed BAA on file, dated [BAA Date].
3. State Mandates: Vendor and Purchaser shall ensure that all screening assays align precisely with the mandatory panel requirements dictated by the Department of Health of the state of [State Jurisdiction].

3.6 Warranties and Indemnification

1. Vendor Warranty: Vendor expressly warrants that all diagnostic kits and laboratory services provided hereunder are merchantable, fit for their intended clinical purpose, free from manufacturing defects, and performed in accordance with Good Laboratory Practices (GLP).
2. Indemnification: Vendor agrees to defend, indemnify, and hold harmless Purchaser, its directors, officers, employees, and agents from and against any third-party claims, liabilities, damages, or regulatory penalties arising directly out of Vendor’s manufacturing defects, gross negligence, willful misconduct, or failure to meet assay specifications.

3.7 Limitation of Liability

Except for breaches of confidentiality, privacy obligations (HIPAA/BAA), intellectual property infringement, or gross negligence/willful misconduct, neither party's aggregate liability under this Purchase Order shall exceed the total PO amount stated herein ([$0,000.00]).

3.8 Governing Law and Dispute Resolution

This Purchase Order shall be governed by and construed in accordance with the laws of the State of [State], without regard to its conflict of laws principles. Any legal action or proceeding arising under this PO shall be brought exclusively in the state or federal courts located in [County, State].

---

SCHEDULE A: ORDER SCHEDULE & PRICING MATRIX

---

4. EXECUTION & SIGNATURES BLOCK

IN WITNESS WHEREOF, the duly authorized representatives of Purchaser and Vendor have executed this Purchase Order as of the Effective Date written below. Both signatories warrant that they possess the corporate authority to bind their respective organizations to these terms.

FOR PURCHASER: [Purchaser Legal Name]

Signature: ____________________________________________________
Printed Name: [Authorized Signatory Name]
Title: [Corporate Title / e.g., Director of Procurement]
Date: [Date]

FOR VENDOR: [Vendor Legal Name]

Signature: ____________________________________________________
Printed Name: [Authorized Signatory Name]
Title: [Corporate Title / e.g., VP of Clinical Operations]
Date: [Date]

---

5. STEP-BY-STEP EXECUTION, FILING, AND ENFORCEMENT GUIDE

1. Pre-Execution Verification:
   • Confirm that an active Master Services Agreement (MSA) and Business Associate Agreement (BAA) are currently in force between Purchaser and Vendor before signing this Purchase Order.
   • Verify that the CLIA number listed for the Designated Clinical Laboratory is active and unencumbered.
2. Data Population:
   • Replace all bracketed placeholder text (e.g., [Company Name], [Amount], dates) with accurate operational data. Ensure exact quantitative alignment between Schedule A line items and the Total Purchase Order Amount.
3. Formal Authorization:
   • Route the completed document to authorized procurement officers and clinical directors for dual-signature execution. Electronic signatures via compliant platforms (e.g., DocuSign, Adobe Sign) are legally valid under ESIGN and UETA frameworks.
4. Filing and Archival:
   • Transmit a fully executed copy to Purchaser’s Legal and Compliance Department, Accounts Payable, and the Vendor's Account Manager. Retain digital copies in a secure, HIPAA-compliant document management repository for a mandatory minimum of [7] years (or longer if mandated by state pediatric retention laws).
5. Enforcement and Logistics Tracking:
   • Attach tracking numbers from the shipping carrier to this file upon dispatch.
   • In the event of an inventory discrepancy, assay failure, or compliance breach, immediately notify the opposing party's designated legal point of contact in writing pursuant to the dispute resolution terms outlined in Section 3.8.